This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sackmann, F. Articles by Pavlovsky, S. Search for Related Content PubMed PubMed Citation Articles by Sackmann, F. Articles by Pavlovsky, S.

Prognostic factors in monoclonal gammopathy of undetermined significance

FUNDALEU, Buenos Aires, Argentina

Correspondence: Federico Sackmann, Fundaleu, Uriburu 1450, 1114 Buenos Aires, Argentina. E-mail: fsackmann{at}fundaleu.org.ar

A retrospective evaluation of 285 patients with monoclonal gammopathy of undetermined significance was performed to identify variables associated with progression, actuarial progression free survival (PFS) and overall survival (OS). Three variables, level of uninvolved immunoglobulins (HR 4.98, CI95% 2 –12.4, p=0.0006), monoclonal protein concentration (HR 4.04, CI95% 1.6–10.34, p=0.004), and erythrosedimentation rate (HR 3.94, CI95% 1.33–11.6, p=0.01), showed independent prognostic significance. With a median follow-up of 66 months (range 6–378), PFS and OS at 10 years were 89% and 91% respectively.

This article has been cited by other articles:

				S. Kapoor TGF-beta 1 and urinary excretion of pyridinium crosslinks: two often overlooked risk factors for assessing risk of progression in patients with monoclonal gammopathy of undetermined significance Haematologica, March 1, 2008; 93(3): e38 - e38. [Full Text] [PDF]